WO2007131129A3 - Déterminants de surface cellulaire associés à l'immunoglobuline dans le traitement de troubles des lymphocytes b - Google Patents

Déterminants de surface cellulaire associés à l'immunoglobuline dans le traitement de troubles des lymphocytes b Download PDF

Info

Publication number
WO2007131129A3
WO2007131129A3 PCT/US2007/068174 US2007068174W WO2007131129A3 WO 2007131129 A3 WO2007131129 A3 WO 2007131129A3 US 2007068174 W US2007068174 W US 2007068174W WO 2007131129 A3 WO2007131129 A3 WO 2007131129A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
surface determinants
immunoglobulin associated
immunoglobulin
associated cell
Prior art date
Application number
PCT/US2007/068174
Other languages
English (en)
Other versions
WO2007131129A2 (fr
Inventor
Sydney Welt
David A Kostyal
Original Assignee
Guthrie Foundation For Educati
Sydney Welt
David A Kostyal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guthrie Foundation For Educati, Sydney Welt, David A Kostyal filed Critical Guthrie Foundation For Educati
Priority to EP07783226A priority Critical patent/EP2021027A4/fr
Priority to JP2009510082A priority patent/JP2009536217A/ja
Priority to AU2007247965A priority patent/AU2007247965A1/en
Priority to CA002651178A priority patent/CA2651178A1/fr
Priority to US12/298,781 priority patent/US20090220416A1/en
Publication of WO2007131129A2 publication Critical patent/WO2007131129A2/fr
Publication of WO2007131129A3 publication Critical patent/WO2007131129A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)

Abstract

La présente invention concerne des procédés, des compositions et des vaccins destinés au ciblage spécifique de déterminants de surface cellulaire associés à l'immunoglobuline qui ne sont pas diffusés dans le sang d'un hôte. Dans certains cas, les déterminants de surface cellulaire associés à l'immunoglobuline seront impliqués dans divers troubles liés aux lymphocytes B. Les procédés consistent à administrer un élément de ciblage IACSD à un lymphocyte B. Le procédé peut consister à traiter un individu souffrant d'un trouble associé aux lymphocytes B en lui administrant une quantité efficace de préparation de ciblage IACSD. Les compositions incluent des anticorps isolés, lesdits anticorps s'associant à des déterminants de surface cellulaire associés à l'immunoglobuline. L'invention inclut également des vaccins qui conduisent à une immunisation contre lesdits déterminants de surface cellulaire associés à l'immunoglobuline.
PCT/US2007/068174 2006-05-03 2007-05-03 Déterminants de surface cellulaire associés à l'immunoglobuline dans le traitement de troubles des lymphocytes b WO2007131129A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP07783226A EP2021027A4 (fr) 2006-05-03 2007-05-03 Déterminants de surface cellulaire associés à l'immunoglobuline dans le traitement de troubles des lymphocytes b
JP2009510082A JP2009536217A (ja) 2006-05-03 2007-05-03 Ｂ細胞障害の治療における免疫グロブリン結合細胞表面決定基
AU2007247965A AU2007247965A1 (en) 2006-05-03 2007-05-03 Immunoglobulin associated cell-surface determinants in the treatment of B-cell disorders
CA002651178A CA2651178A1 (fr) 2006-05-03 2007-05-03 Determinants de surface cellulaire associes a l'immunoglobuline dans le traitement de troubles des lymphocytes b
US12/298,781 US20090220416A1 (en) 2006-05-03 2007-05-03 Immunoglobulin associated cell-surface determinants in the treatment of b-cell disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79728606P 2006-05-03 2006-05-03
US60/797,286 2006-05-03

Publications (2)

Publication Number Publication Date
WO2007131129A2 WO2007131129A2 (fr) 2007-11-15
WO2007131129A3 true WO2007131129A3 (fr) 2008-11-27

Family

ID=38668568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/068174 WO2007131129A2 (fr) 2006-05-03 2007-05-03 Déterminants de surface cellulaire associés à l'immunoglobuline dans le traitement de troubles des lymphocytes b

Country Status (6)

Country Link
US (1) US20090220416A1 (fr)
EP (1) EP2021027A4 (fr)
JP (1) JP2009536217A (fr)
AU (1) AU2007247965A1 (fr)
CA (1) CA2651178A1 (fr)
WO (1) WO2007131129A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY183134A (en) 2009-02-25 2021-02-15 Academia Sinica Anti-cemx antibodies capable of binding to human mlge on b lymphocytes
US9587034B2 (en) 2012-04-20 2017-03-07 Academia Sinica Anti-mIgE antibodies that bind to the junction between CH4 and CεmX domains
SG10201709164UA (en) * 2013-12-03 2017-12-28 Welt Bio-Molecular Pharmaceutical Llc Antibodies Targeting B-Cell Receptor Complex Membrane Bound IgM and Uses Thereof
WO2018222506A1 (fr) * 2017-05-27 2018-12-06 Immune-Onc Therapeutics, Inc. Modulation de cellules à immunoglobuline a positive
JP7286665B2 (ja) 2017-10-31 2023-06-05 ワンネス バイオテック カンパニー リミティド ＩｇＥ介在アレルギー性疾患の治療

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US20020039557A1 (en) * 2000-06-20 2002-04-04 Christine White Treatment of B-cell associated diseases such as malignances and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254671A (en) * 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
US5274075A (en) * 1987-12-31 1993-12-28 Tanox Biosystems, Inc. Newly identified human epsilon immunoglobulin peptides and related products
ES2107454T3 (es) * 1990-01-23 1997-12-01 Tanox Biosystems Inc Segmentos extracelulares de peptidos de anclaje de la inmunoglobulina ige humana, y anticuerpos especificos para los mismos.
US5281699A (en) * 1990-06-01 1994-01-25 Tanox Biosystems, Inc. Treating B cell lymphoma or leukemia by targeting specific epitopes on B cell bound immunoglobulins
US5298420A (en) * 1990-08-03 1994-03-29 Tanox Biosystems, Inc. Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface
AU4012095A (en) * 1994-10-25 1996-05-15 United Biomedical Inc. Synthetic ige membrane anchor peptide immunogens for the treatment of allergy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US20020039557A1 (en) * 2000-06-20 2002-04-04 Christine White Treatment of B-cell associated diseases such as malignances and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANDERSON ET AL.: "Targeting Cytotoxic Immunotherapy", BIOCHEM. SOC. TRANS., vol. 25, 1997, pages 705 - 708, XP008101434 *
MANSFIELD E. ET AL.: "Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells", BIOCHEM. SOC. TRANS., vol. 25, 1997, pages 709 - 714, XP002074957 *
See also references of EP2021027A4 *

Also Published As

Publication number Publication date
AU2007247965A1 (en) 2007-11-15
CA2651178A1 (fr) 2007-11-05
US20090220416A1 (en) 2009-09-03
WO2007131129A2 (fr) 2007-11-15
EP2021027A4 (fr) 2010-01-27
EP2021027A2 (fr) 2009-02-11
JP2009536217A (ja) 2009-10-08

Similar Documents

Publication Publication Date Title
WO2009133521A3 (fr) Anticorps et vaccins pour utilisation dans des procédés thérapeutiques et diagnostiques pour les troubles associés à l’alpha-synucléine
NZ603883A (en) Method for preparing antibodies having improved properties
WO2006126981A3 (fr) Compositions et methodes destinees a la vaccination par voie muqueuse
MX2009010765A (es) Anticuerpos anti-ige.
NZ599875A (en) Human il-23 antigen binding proteins
WO2010066803A3 (fr) Anticorps humains du facteur tissulaire
MX2010006823A (es) Metodos para el tratamiento de la gota.
WO2010113117A3 (fr) Préparation d'anticorps monoclonaux anti-edar agonistes isolés
WO2010096418A3 (fr) Molécules d'anticorps ayant une spécificité pour ox40 humain
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
WO2006108670A3 (fr) Utilisation d'anticorps cd25 en immunotherapie
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
WO2009083009A3 (fr) Anticorps monoclonaux anti-cd32b
JO2576B1 (en) Antibodies
WO2008154251A3 (fr) Anticorps c3b et procédés de prévention et de traitement de troubles associés à un complément
WO2010136311A3 (fr) Compositions et procédés de ciblage de la protéine c3b de complément par des anticorps
WO2008116078A8 (fr) Stimulation d'une réponse immunitaire par des lipides cationiques
WO2012054723A3 (fr) Traitement de maladies associées à l'alpha-l-iduronidase (idua) par inhibition du transcrit antisens endogène de idua
WO2006076651A3 (fr) Procede de traitement
WO2009060281A3 (fr) Analogues d'oligoribonucléotides immunostimulants contenant des fractions oligophosphates modifiées
WO2008033966A3 (fr) Particules de réplicon d'alphavirus correspondant à des antigènes de protéines utilisées en qualité d'adjuvants immunologiques
WO2008034076A3 (fr) Utilisation de cyclophosphamide à doses élevées en combinaison avec des thérapeutiques d'immunisation dans le traitement anticancer
WO2008034074A3 (fr) Utilisation de cyclophosphamide à doses élevées en combinaison avec des vaccins anti-idiotypiques dans le traitement anticancéreux
WO2006080549A3 (fr) Procede et composition de traitement de troubles du systeme nerveux central
WO2009090656A3 (fr) Polythérapie à base de bêta-glycolipides et d'anticorps pour le traitement de troubles de nature immunitaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07783226

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007247965

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12298781

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2009510082

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2651178

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007247965

Country of ref document: AU

Date of ref document: 20070503

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007783226

Country of ref document: EP